文献速递心脏核医学

如何在临床实践中建立123I-mIBG心脏交感神经显像:日本与美国的经验与教训

How do we establish cardiac sympathetic nervous system imaging with 123I-mIBG in clinical practice? Perspectives and lessons from Japan and the US.
PubMed 文献 · J Nucl Cardiol · 2018-09-03

心脏去神经支配与心力衰竭患者左心室功能恶化、室性心律失常及心源性猝死相关,123I-mIBG可无创评估突触前交感神经功能。日本于1992年批准123I-mIBG用于心功能评估并发展显像服务,美国FDA已批准其临床使用但临床应用非常有限,两国在123I-mIBG应用上存在异同,需分别了解各自情况以确立其临床效用。

要点

  • 123I-mIBG可无创评估心脏突触前交感神经功能,近期多中心试验显示其对心衰患者致命性心律失常和心源性死亡有强预测价值。
  • 日本厚生劳动省于1992年批准123I-mIBG用于心功能评估,日本核心脏病学界随后在多中心发展显像服务并尝试标准化采集与分析参数。
  • 美国FDA已批准123I-mIBG用于心脏和非心脏显像,但美国临床应用非常有限,日本研究数量也有限。

核心结论

  • 为在两国确立123I-mIBG的临床效用,重要的是分别了解两国123I-mIBG的应用现状。

研究设计与样本

  • 本文为综述,比较日本与美国在临床实践中建立123I-mIBG心脏交感神经显像的经验与教训。

主要发现

  • 心脏去神经支配与心力衰竭患者进行性左心室功能恶化、室性心律失常和心源性猝死相关。
  • 123I-mIBG可无创评估突触前交感神经功能,近期多中心试验显示其对心衰患者致命性心律失常和心源性死亡有强预测价值。
  • 美国FDA已批准123I-mIBG用于心脏和非心脏显像,但美国临床应用非常有限,日本研究数量也有限。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cardiac denervation is associated with progressive left ventricular (LV) dysfunction, ventricular arrhythmias, and sudden cardiac death (SCD) in heart failure (HF). In this regard, it is important to evaluate cardiac-specific sympathetic nervous system (SNS) function. The radiotracer Iodine-123 meta-iodobenzylguanidine (123I-mIBG) can noninvasively evaluate pre-synaptic SNS function. Recent multicenter trials have shown 123I-mIBG to have strong predictive value for fatal arrhythmias and cardiac death in HF. 123I-mIBG was initially developed in the USA in the 1970s. In 1992, the Japanese Ministry of Health and Labour approved 123I-mIBG for the assessment of cardiac function. Following approval, the Japanese nuclear cardiology community developed 123I-mIBG imaging services in various medical centers. Japanese groups have been trying to establish the clinical utility of 123I-mIBG and standardize parameters for data acquisition and image analysis. The US Food and Drug Administration (FDA) has approved clinical use of 123I-mIBG for cardiac and non-cardiac imaging. However, clinical use of 123I-mIBG in the US has been very limited. The number of 123I-mIBG studies in Japan has also been limited. There are similarities and differences between the two countries. To establish the clinical utility of 123I-mIBG in both countries, it is important to characterize the situations of 123I-mIBG in each.

来源:J Nucl Cardiol,查看原文。版权归原作者所有。

引用

  1. Travin MI, Matsunari I, Thomas GS, et al. How do we establish cardiac sympathetic nervous system imaging with 123I-mIBG in clinical practice? Perspectives and lessons from Japan and the US. J Nucl Cardiol. 2018. PMID: 30178272. doi:10.1007/s12350-018-1394-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。